A lot more to digest from the report, but what I read below is quite compelling so clinical efficacy is almost proven in Japanese jurisdiction but for different use
Ann: Half-Year Financial Report & Appendix 4D - 31 December 2023, page-3
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
-0.015(3.09%) |
Mkt cap ! $257.2M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 47.5¢ | 46.5¢ | $757.3K | 1.617M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 20042 | 47.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.5¢ | 188364 | 7 |
View Market Depth
| Last trade - 12.43pm 25/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |